No Data
No Data
Express News | Kangyuan Pharmaceutical: Received a notice of approval for the clinical trial of Shichimi Fatty Liver Granules
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings May Just Be The Starting Point
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We have done some analysis and have found so
Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross mar
Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross margin of tablets and capsules, while the remaining dosage forms have decreased to varying degrees; 3) increased R&D investment and cost rate optimization. (Mainichi Keizai Shimbun)
Kangyuan Pharmaceutical (600557) Review Report: Outstanding Performance of Oral Medications, Cost Optimization
Key elements of the report: On April 13, 2024, the company released its 2024 quarterly report. 2024Q1, the company achieved operating income of 1,359 million yuan (+0.48%) and net profit of 148 million yuan to mother (
China Post Securities released a research report on April 17 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) revenue: rapid growth in oral liquid, slight decline in injections due t
China Post Securities released a research report on April 17 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) revenue: rapid growth in oral liquid, slight decline in injections due to a high base; 2) profit: gross margin declined slightly, rate control was good, and profitability was stable; 3) continuous optimization of operational efficiency, good repayment, and sufficient cash; 4) R&D results continued to be implemented. (Mainichi Keizai Shimbun)
Kangyuan Pharmaceutical (600557): Recovery of oral formulations with excellent report quality
Core idea On the evening of April 12, the company released its report for the first quarter of 2024, achieving operating income of 1,359 million yuan, an increase of 0.48% over the previous year; net profit to mother of 148 million yuan, an increase of 4.67% over the previous year.
No Data